

Presente e futuro delle strategie di trattamento dell'infezione da HIV

Giovanni Cenderello
Direttore
SC Malattie Infettive
ASL1 Imperiese




Figura 1 - Nuove diagnosi di infezione da HIV e incidenze corrette per ritardo di notifica (2012-2022)





Figura 2 - Incidenza delle nuove diagnosi di infezione da HIV per genere, età e anno di diagnosi (2012-2022)


Incidenza HIV ed AIDS


Late presenters 2022*



Modalità di trasmissione

Modalità di trasmissione 2022





1028. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERA® Cohort

Table 1. Baseline^a characteristics of individuals with CAB+RPV LA injections

		VL ≥50 copies/mL at initiation N = 229	VL ≥200 copies/mL at initiation N = 93
Age	Median years (IQR)	41 (33, 52)	40 (32, 48)
Female sex	n (%)	71 (31)	44 (47)
Race	Asian, n (%)	≤5 (≤2) ^b	0 (0)
	Black, n (%)	130 (57)	65 (70)
	White, n (%)	80 (35)	22 (24)
	Other/Mixed, n (%)	9 (4)	≤5 (≤5) ^b
	Unknown, n (%)	8 (4)	≤5 (≤5) ^b
Ethnicity	Hispanic, n (%)	40 (17)	8 (9)
	Not Hispanic, n (%)	184(80)	83 (89)
	Unknown, n (%)	≤5 (≤2) ²	≤5 (≤5) ^b
BMI	Median kg/m ² (IQR)	27 (24, 31)	27 (22, 31)
HIV Risk Factors	MSM only, n (%)	105 (46)	33 (35)
	IDU + MSM, n (%)	≤5 (≤2) ^b	≤5 (≤5) ^b
	IDU only, n (%)	≤5 (≤2) ^b	≤5 (≤5) ^b
	Other, n (%)	114 (50)	53 (57)
Time from HIV diagnosis	Median years (IQR)	9 (4, 17)	9 (4, 16)
Viral load at first injection	Log median (IQR) copies/mL	2.1 (1.8, 3.8)	4.2 (3.2, 4.7)

Hsu RK, Sension M, Fusco JS, Brunet L, Cochran Q, Sridhar G, Vannappagari V, van Wyk JA, Wohlfeiler MB, Fusco GP. 1028. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERA® Cohort. Open Forum Infect Dis. 2023 Nov 27;10(Suppl 2):ofad500.059. doi: 10.1093/ofid/ofad500.059. PMID: PMC10678653

1028. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERA® Cohort

Table 2. Virologic outcomes^a of individuals with CAB+RPV LA injections^b

	VL ≥50 copies/mL at initiation N = 221	VL ≥200 copies/mL at initiation N = 87
Months of follow-up ^c , median (IQR)	6.1 (3.5, 10.1)	7.4 (3.9, 10.9)
Died, n (%)	0 (0)	0 (0)
On CAB+RPV LA at end of follow-up, n (%)	183 (83)	72 (83)
≥1 VL after first injections, n (%)	176 (80)	69 (80)
Achieved VL <200 copies/mL, n (%)	NA	62 (90)
Achieved VL <50 copies/mL, n (%)	145 (82)	52 (74)
Last VL <200 copies/mL, n (%)	166 (94)	62 (90)
Last VL <50 copies/mL, n (%)	132 (75)	51 (74)
Confirmed virologic failure ^d , n (%)	7 (4)	≤5 (≤6) ^e

CAB+RPV LA=cabotegravir + rilpivirine long-acting, IQR=interquartile range, BMI=body mass index

^a From first CAB+RPV injections to discontinuation or last follow up

^b 8 individuals have no dose information on all their injection records and were excluded from this table

^c Calculated from first CAB+RPV injections to discontinuation or last follow up

^d 2 consecutive VLs >200 copies/mL or 1 VL >200 copies/mL followed by discontinuation after a VL<50 copies/mL

Hsu RK, Sension M, Fusco JS, Brunet L, Cochran Q, Sridhar G, Vannappagari V, van Wyk JA, Wohlfeiler MB, Fusco GP. 1028. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERA® Cohort. Open Forum Infect Dis. 2023 Nov 27;10(Suppl 2):ofad500.059. doi: 10.1093/ofid/ofad500.059. PMID: PMC10678653